Lepirudin

Lepirudin (Refludan) was a real, FDA-approved recombinant hirudin analog — the first direct thrombin inhibitor approved for heparin-induced thrombocytopenia (HIT) — discontinued in 2012 for commercial reasons after cheaper alternatives took over the market, not because of a safety failure, though a real fatal-anaphylaxis signal did exist on re-exposure.

The first approved HIT-specific anticoagulant

Lepirudin is a recombinant hirudin analog, the same broad class as desirudin, approved by the FDA in 1998 as the first direct thrombin inhibitor specifically for heparin-induced thrombocytopenia (HIT) — a dangerous, antibody-mediated paradoxical clotting reaction some patients develop to heparin itself, which obviously rules out heparin as the treatment. Lepirudin gave clinicians a genuinely non-heparin anticoagulant option at a time when few existed.

The evidence, and a real limitation

The approval rested on the HAT (Heparin-Associated Thrombocytopenia) studies run by Greinacher and colleagues: HAT-1 (Circulation 1999, PMID 9884382) treated 82 patients across four lepirudin dosing regimens, and HAT-2 (Circulation 1999, PMID 10441094) compared 95 lepirudin-treated patients against 120 historical controls who had not received lepirudin. Worth being precise about: these were prospective but historically-controlled studies, not randomized controlled trials against a concurrent comparator — a real evidentiary limitation common to rare-disease anticoagulant approvals of that era, not a flaw specific to lepirudin.

Why it disappeared

Two separate, real facts apply here and shouldn't be conflated. First, a genuine safety signal existed: regulators issued public warnings about fatal anaphylactic reactions on lepirudin re-exposure in previously-sensitized patients, a real and serious risk. Second, and separately, Bayer/Baxter Healthcare discontinued production for commercial reasons, with no product distributed after May 2012 — by then, bivalirudin and argatroban had become preferred alternatives on cost and familiarity grounds, and demand for lepirudin specifically had declined enough that the manufacturer chose to exit rather than continue supplying it. The company's own stated reason was commercial, not a directive tied to the anaphylaxis signal — but a reader comparing this to other case studies on this site should know the safety signal was real, even though it wasn't the stated cause of discontinuation.